Making a Difference with Early Identification and Treatment of Patients with NTRK Gene Fusions

Ezra Cohen, MD, FRCPSC, FASCO; Mary Jo Fidler, MD; Arturo Loaiza-Bonilla, MD, MSEd, FACP

Video Categories: NTRK Gene Fusions

Dr Ezra Cohen of UC San Diego, La Jolla, CA; Dr Mary Fidler of Rush University Medical Center, Chicago, IL; and Dr Arturo Loaiza-Bonilla of the Comprehensive Care and Research Center, Philadelphia, PA, explain the benefits of testing for TRK fusion–positive tumors early for improved clinical outcomes.

September 20, 2013

The Pricing Evolution of Personalized Medicines

Grant Lawless discusses the changing landscape of pricing personalized medicines

June 16, 2015

The Biomarker: Melanoma

PMO is pleased to offer the department “The Biomarker” to discuss the identification of biomarkers in patients with cancer and the prognostic/predictive impact and clinical decision-making implications of that marker. This month, we focus on KIT mutations in melanoma patients. Dr Sanjiv Agarwala provides his insights on this provocative topic.